A detailed history of Gts Securities LLC transactions in Biogen Inc. stock. As of the latest transaction made, Gts Securities LLC holds 21,000 shares of BIIB stock, worth $3.16 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares
21,000
Previous 18,300 14.75%
Holding current value
$3.16 Million
Previous $4.24 Million 4.05%
% of portfolio
0.01%
Previous 0.01%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

SELL
$189.07 - $236.8 $117,979 - $147,763
-624 Reduced 4.48%
13,294 $2.58 Million
Q2 2024

Aug 14, 2024

BUY
$190.52 - $236.72 $2.65 Million - $3.29 Million
13,918 New
13,918 $3.23 Million
Q4 2023

Feb 14, 2024

BUY
$222.59 - $267.94 $146,464 - $176,304
658 Added 4.29%
15,981 $4.14 Million
Q3 2023

Nov 15, 2023

BUY
$253.3 - $285.89 $1.07 Million - $1.21 Million
4,235 Added 38.19%
15,323 $3.94 Million
Q2 2023

Aug 15, 2023

BUY
$275.25 - $318.06 $3.05 Million - $3.53 Million
11,088 New
11,088 $3.16 Billion

Others Institutions Holding BIIB

About BIOGEN INC.


  • Ticker BIIB
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 144,000,992
  • Market Cap $21.7B
  • Description
  • Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an eta...
More about BIIB
Track This Portfolio

Track Gts Securities LLC Portfolio

Follow Gts Securities LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Gts Securities LLC, based on Form 13F filings with the SEC.

News

Stay updated on Gts Securities LLC with notifications on news.